AS A CONSEQUENCE of its admission to the AIM Market, UK polymer company Revolymer has appointed Julian Heslop to its board as a non-executive director.
Heslop served as CFO of GlaxoSmithKline between April 2005 and March 2011. He was also Chairman of ViiV Healthcare until March 2011.
He served as senior vice president, operations controller of GSK between January 2001 and March 2005 and as financial controller of Glaxo Wellcome from April 1998 to December 2000.
Previously, Heslop had senior finance roles at Grand Metropolitan and Imperial Brewing and Leisure.
He is a fellow of the ICAEW.
Revolymer placed shares onto the exchange to raise £25m from institutional investors, and its market cap at the time of its listing will be approxiamtely £53m. The proceeds will be used to expand its distribution of its confectionary gum products in the US and Europe, fund regulatory documentation around the nicotine gum industry, and develop new products.
Its share price is 103.5p in this morning’s trading.
For more company and market information visit the Share Price Centre
Does Darwin's theory apply to taxation? Colin ponders...
The EC has been instructed to draft a European Union (EU) directive authorising an EU financial transaction tax, which would apply to ten of the EU’s 28 member states
Accountancy Age Jobs is delighted to announce the launch of a brand new look website for finance and accountancy professionals
The UK gender pay gap will not close until 2069 unless action is taken to tackle it now, according to new research by Deloitte